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Acute stress is associatedwith a sensitized amygdala. Corticosteroids, released in response to stress, are suggested to restore homeostasis
by normalizing/desensitizing brain processing in the aftermath of stress. Here, we investigated the effects of corticosteroids on amygdala
processing using functional magnetic resonance imaging. Since corticosteroids exert rapid nongenomic and slow genomic effects, we
administered hydrocortisone either 75 min (rapid effects) or 285 min (slow effects) before scanning in a randomized, double-blind,
placebo-controlled design. Seventy-two healthy males were scanned while viewing faces morphing from a neutral facial expression
into fearful or happy expressions. Imaging results revealed that hydrocortisone desensitizes amygdala responsivity rapidly, while
it selectively normalizes responses to negative stimuli slowly. Psychophysiological interaction analyses suggested that this slow
normalization is related to an altered coupling of the amygdala with the medial prefrontal cortex. These results reveal a tempo-
rarily fine-tuned mechanism that is critical for avoiding amygdala overshoot during stress and enabling adequate recovery
thereafter.
Introduction
It is of vital importance to an organism to respond adequately to
potential threats during the exposure to a stressful experience,
but also to subsequently recover when the threat has subsided.
The immediate central release of norepinephrine (NE) during the
initial phase of the stress response is known to induce a surge of
vigilance, which optimizes the detection and assessment of these
threats by prioritizing sensory processing (de Kloet et al., 2005)
and activating the keymodulator of vigilance and emotional pro-
cessing in the brain: the amygdala (Phelps and LeDoux, 2005; van
Marle et al., 2009). Whereas this amygdala-mediated hypervigi-
lant state of processing is highly beneficial during an initial fight-
or-flight response, it may become maladaptive and culminate in
mental diseases such as depression or post-traumatic stress dis-
order (PTSD) if this sensitization is not properly controlled
(McEwen, 2004; de Kloet et al., 2005).
Corticosteroids, released at a slightly slower time scale in re-
sponse to stress, have been suggested to be crucial factors in this
regulation of the stress response (de Kloet et al., 2005). They
restore homeostasis by diverting energy supply to challenged tis-
sues and control the excitability of neuronal networks (deKloet et
al., 1999). Therefore, it can be hypothesized that they regulate
amygdala activation and thus normalize vigilance in the after-
math of stress. Initial evidence for such a regulatory role of cor-
ticosteroids was derived from animal studies showing that
corticosteroids induce anxiolytic effects in rodents (File et al.,
1979; Andreatini and Leite, 1994). Corticosteroid administration
resulted in more explorative and socially interactive behavior in
rats, which was the exact opposite effect of acute stress. Recent
studies have extended these findings to humans (Soravia et al.,
2006; Het and Wolf, 2007; Putman et al., 2007). Remarkably,
these anxiolytic effects occur relatively instantly. This goes
against the general assumption that the normalizing effects occur
gradually by a process involving gene transcription (de Kloet et
al., 2005), but suggests that rapid nongenomic effects are in-
volved as well.
To elucidate the role of corticosteroids in vigilance regulation,
we targeted both the rapid nongenomic and the slow genomic
effects of corticosteroids on amygdala function. To assess the
dynamic corticosteroid effects over time, we used a randomized,
double-blind, placebo-controlled design, in which healthy male
participants received either 10 mg of hydrocortisone at 75 min
(targeting the rapid effects) or 285 min (targeting the slow ef-
fects), or placebo before a task probing amygdala reactivity (van
Marle et al., 2009) during functionalmagnetic resonance imaging
(fMRI). Timing of hydrocortisone administration was based on
animal work targeting the nongenomic and genomic effects of
corticosteroids. The task consisted of passive viewing of photo-
graphed faces morphing from a neutral expression into a fearful
or happy facial one (supplemental Fig. S1, available at www.
jneurosci.org as supplemental material), allowing us to test
whether the normalization is specific for certain emotional input.
Additionally, we used functional connectivity analyses to test
whether corticosteroids affect amygdala coupling to brain re-
gions involved in its control.
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Materials andMethods
Participants
Seventy-two young (age range, 18–29 years; median age, 21 years), right-
handed, healthy male volunteers gave informed consent to participate in
the study. To ensure stable effects of hydrocortisone over all participants,
women were excluded from participation. Women are known to display
different hypothalamic-pituitary-adrenal (HPA) axis activity than men,
exhibiting smaller and more variable cortisol responses to stress (Kajan-
tie andPhillips, 2006), depending onmenstrual cycle phase and the use of
hormonal contraceptives (Kirschbaum et al., 1999; Bouma et al., 2009).
Furthermore, individuals who met any of the following criteria were
excluded from participation: history of head injury; autonomic failure;
history of or current psychiatric, neurological, or endocrine disorders;
current periodontitis; acute inflammatory disease; acute peptic or duo-
denal ulcers; regular use of corticosteroids; treatment with psychotropic
medications, narcotics, -blockers, steroids, or any other medication
that affects CNS or endocrine system; medical illness within the 3 weeks
before testing; self-reported mental or substance use disorder; daily to-
bacco or alcohol use; regular night-shift work; or current stressful epi-
sode or major life event. Moreover, volunteers with high scores on
depression (score 8 on the Beck Depression Inventory) (Beck et al.,
2002)were excluded fromparticipation. Four participantswere excluded
from analyses because they either displayed abnormal basal salivary cor-
tisol levels (3 SDs abovemean; 1 participant) or showed no elevation in
salivary cortisol level in response to hydrocortisone (CORT) intake,
which means we ended up with 23 men in the placebo group, 23 in the
slow CORT group, and 22 in the rapid CORT group. The study was
approved by the local ethics committee [Commissie Mensgebonden
Onderzoek (CMO) region Arnhem-Nijmegen, The Netherlands] and in
accordance with the declaration of Helsinki.
Study design
Participants were scanned in a randomized, double-blind, placebo-
controlled, parallel-group design. To target the time-differential effects
of CORT, participants were divided over three groups, receiving 10mg of
CORT at either 75 min (rapid CORT effects) or 285 min (slow CORT
effects), or placebo before viewing an emotional processing task in the
MRI scanner. Physiological (cortisol level) and psychological (mood and
attention) indices were measured to confirm cortisol level manipulation
without additional side effects.
Procedure
Before arrival. Before inclusion, all eligible participants received an ex-
tensive information brochure, listing all inclusion and exclusion criteria
and explaining the setup of the experiment. If criteria were met (accord-
ing to the participant’s own insights), an appointment was made. To
minimize differences in baseline cortisol levels, we instructed partici-
pants not to use any recreational drugs for 3 d, and to refrain from
drinking alcohol, exercising, and smoking for 24 h before the appoint-
ment. Furthermore, participants were requested not to brush their teeth,
floss, or eat and drink anything but water for 1 h before the session,
enabling adequate saliva sampling for cortisol assessment. They were
asked to take a light lunch and do so no later than 1 h before arrival; their
lunch could not contain any citrus products, coffee, tea, milk, or sweets
(Maheu et al., 2005). Throughout the entire study period, participants
were given only water to drink, except for a scheduled lunch at 135 min
after arrival. To reduce the impact of diurnal variation in cortisol levels,
all testing was performed in the afternoon, between 12:00 P.M. (30
min) and 6:00 P.M. (30 min), when hormone levels are relatively
stable.
Arrival. Upon arrival, participants received an information brochure
about the procedure, they gavewritten informed consent, and completed
an intake questionnaire to ensure that inclusion and exclusion criteria
were met. Thirty minutes after arrival, a first saliva sample was taken,
followed by another one 15min later, tomeasure a reliable baseline level.
Participants were then asked to complete theNEO-Five Factor Inventory
(FFI) Personality Inventory (Costa and McCrae, 1992), the Spielberger
Trait Anxiety Inventory (trait anxiety) (van der Ploeg et al., 1980; van der
Ploeg, 1981), and a first Profile of Mood States (POMS) questionnaire
(Reddon et al., 1985; Wald and Mellenbergh, 1990; de Groot, 1992).
Immediately after the second saliva sample (at t 45 min) participants
received the first capsule, containing either 10 mg of CORT or placebo.
During the entire period (3.5 h) before scanning, the participants had
to wait in a quiet room where they were free to conduct any activities
except for anything potentially arousing (e.g., video games). At 255 min
after arrival, participants were asked to complete a second POMS
questionnaire and received the second capsule. Both drug capsules,
containing either 10 mg of CORT or placebo (cellulose), were admin-
istered orally. This dose is known to elevate salivary cortisol levels to
high-stress levels (Kirschbaum et al., 1996; Gro¨schl et al., 2002; Tops et
al., 2003). Depending on the group to which participants were (ran-
domly) assigned, they received the first capsule containing placebo, the
second containing placebo (placebo condition); the first capsule placebo,
the second CORT (rapid CORT condition); or the first capsule CORT,
the second placebo (slow CORT condition).
Scanning. At4.5 h after arrival, participants were taken to the scan-
ner room and the procedures were explained. Participants lay supine in
the scanner and viewed the screen through a mirror positioned on the
head coil. They were asked to lie as still as possible, keep their eyes open,
and look directly and continuously at the center of the screen in front of
them.
Dynamic facial expression task. The dynamic facial expression task
started 75min after administration of the second capsule (at t 330min)
(Fig. 1). In brief, participants were asked to passively view blocks of faces
morphing dynamically into either a fearful or happy facial expression.
The perceptual processing of emotional faces has been shown to robustly
engage the amygdala (Vuilleumier and Pourtois, 2007) and evenmore so
with a dynamic rather than static presentation (Sato et al., 2004). Stimuli
consisted of short 133 ms animation clips for each of 10 different faces
[taken from a standardized set (Ekman and Friesen, 1976) and equalized
in luminance and contrast], showing a morphing sequence consisting of
four frames (55, 70, 85, and 100%emotional expression).Within a block,
each of thesemorphing sequences was immediately followed by themor-
phing sequence of a different face, resulting in the presentation of distinct
faces every 0.5 s. An experimental session lasted 8 min and consisted of
six blocks of each emotion (25 s, 50 morphing sequences each) and six
blocks of fixation cross (25 s, baseline for analysis). Blockswere presented
in a mirrored design avoiding covariation with linear drift, and adjacent
blocks of the same emotion were avoided. Participants were asked to
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Figure 1. Experimental design and salivary cortisol curves. Participants received two cap-
sules (drug1 and drug2) containing either 10 mg of CORT or placebo at different time points
before the emotional processing task. Hydrocortisone intake significantly elevated salivary cor-
tisol levels in both hydrocortisone administration conditions to levels observed during
moderate-to-severe stress. mood, POMS questionnaire (Reddon et al., 1985;Wald andMellen-
bergh, 1990; de Groot, 1992). Error bars represent SEM.
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make a right index finger response on a button boxwhenever the fixation
cross appeared, as a control for attention.
Physiological and psychological measures
Saliva collection and analysis.Cortisol levels weremeasured from saliva at
10 time points: baseline measurements at the beginning of the experi-
ment (t 30, 45min), and eight samples (t 75, 105, 135, 255, 275, 315,
345, and 375 min) to assess cortisol changes throughout the experiment.
Saliva was collected using a commercially available collection device
(Salivette, Sarstedt). For each sample, the participant first placed the
cotton swab provided in each Salivette tube in his mouth and chewed
gently on it for 1min to produce saliva. The swabwas then placed back in
the Salivette tube, and the samples were stored in a freezer at25°C until
assayed. Laboratory analyses were performed at the Department of Bio-
psychology, Technische Universita¨t Dresden (Dresden, Germany). After
thawing, Salivettes were centrifuged at 3000 rpm for 5 min, which
resulted in a clear supernatant of low viscosity. Salivary free cortisol
concentrations were subsequently measured using a commercially
available chemiluminescence immunoassay with a high sensitivity of
0.16 ng/ml (IBL).
Mood state. Mood state was assessed using the POMS questionnaire
(Reddon et al., 1985; Wald and Mellenbergh, 1990; de Groot, 1992) at
three time points: at the beginning of the experiment (t 30 min); just
before the intake of the second capsule (t 255 min); and at the end of
the experiment (t 375 min).
Attention. Average reaction times to appearance of the fixation cross
were calculated to assess the participant’s attentiveness.
Physiological and psychological statistical analysis
Behavioral and physiological data were analyzed in SPSS 15.0 (SPSS)
using repeated measures ANOVAs with emotion type (fearful vs happy)
as the within-subject factor and drug condition (placebo vs rapid CORT
vs slowCORT) as the between-subject factor. The level of neuroticism (as
assessed by the NEO-FFI Personality Inventory) (Costa and McCrae,
1992) was included as covariate. Due to the high levels of skewness and
kurtosis of the POMS questionnaire (Reddon et al., 1985; Wald and
Mellenbergh, 1990; de Groot, 1992), mood data were analyzed using
nonparametric tests. Changes over time in mood state were assessed by
Friedman tests, and Kruskal–Wallis tests were used to assess potential
drug effects on mood. The  was set at 0.05 throughout.
MRI acquisition
Participants were scanned by a Siemens MAGNETOM Avanto 1.5 tesla
MRI scanner equipped with an eight-channel head coil. A series of blood
oxygenation level-dependent T2-weighted gradient echo planar imaging
(EPI) imageswas acquiredwith the following parameters: repetition time
(TR) 2340ms; echo time (TE) 35ms; flip angle (FA) 90 °; 32 axial
slices approximately aligned with anterior commissure-posterior com-
missure plane; slicematrix size 64 64; slice thickness 3.5mm; slice
gap 0.35 mm; and field of view (FOV) 212 212 mm2. Because of
its relatively short TE, this sequence yields optimal contrast-to-noise
ratio in the medial temporal lobes (Sto¨cker et al., 2006). High-resolution
anatomical images were acquired for individuals by a T1-weighted three-
dimensional magnetization-prepared rapid gradient echo sequence,
which used the following parameters: TR  2250 ms; TE  2.95 ms;
FA 15 °; orientation, sagittal; FOV 256 256mm2; and voxel size
1.0 mm isotropic.
fMRI data analysis
Data were analyzed using Statistical Parametric Mapping software
(SPM5; UCL). The first five EPI volumes were discarded to allow for T1
equilibration. Before analysis, the images were motion corrected using
rigid body transformations and least sum of squares minimization. Sub-
sequently, they were temporally adjusted to account for differences in
sampling times across different slices. All functional images were then
coregistered with the high-resolution T1-weighted structural image us-
ing normalized mutual information maximization. The anatomical im-
age was subsequently used to normalize all scans into Montreal
Neurological Institute (MNI) 152 space. All functional images were re-
sampled to a voxel size of 2 mm isotropic. Finally, all images were
smoothed with an isotropic 8 mm full-width-at-half-maximum Gauss-
ian kernel to accommodate residual functional/anatomical variance be-
tween subjects.
Data were analyzed using a general linear model, in which blocks were
modeled based on emotion type. Regressors were temporally convolved
with the canonical hemodynamic response function of SPM5. The six
covariates corresponding to the movement parameters obtained from
the realignment procedure were also included in the model. To reduce
unspecific differences between scan sessions, and to correct for any un-
specific, global effects of drug intake on hemodynamic response instead
of neuronal activation (Desjardins et al., 2001; Peeters and Van der Lin-
den, 2002), global normalization using proportional scaling was applied.
Although this method might induce certain artifacts when local effects
are strong enough to contribute substantially to global signal changes
(Junghofer et al., 2005), all critical comparisons in this study (those be-
tween drug conditions) remain valid since this potential problem is sim-
ilarly present in all drug conditions. The single subject parameter
estimates from each session and condition obtained from the first-level
analysis were included in subsequent random-effects analyses. For the
second-level analysis, a factorial ANOVA was used, with emotion type
(fearful vs happy) as the within-subject factor, drug condition (placebo
vs rapid CORT vs slowCORT) as the between-subject factor, and level of
neuroticism (as assessed by the NEO-FFI Personality Inventory) (Costa
andMcCrae, 1992), which is known to influence amygdala activity (Haas
et al., 2007), as the covariate.
Given the abundance of glucocorticoid receptors (GRs) andmineralo-
corticoid receptors (MRs) in both the amygdala (de Kloet, 1991) and
medial prefrontal cortex (mPFC), and their involvement in emotional
processing (Joe¨ls et al., 2004; Ochsner and Gross, 2005), these regions
were considered regions of interest. Data concerning these a priori re-
gions of interest were corrected for reduced search volumes through
anatomical masks as defined by theWFU PickAtlas Tool (version 2.4). A
threshold of p  0.05 whole-brain corrected was applied to all other
regions. Visualizations of activations were created in SPM5 by superim-
posing statistical parametric maps thresholded at p 0.001 uncorrected
(unless specified otherwise) onto a canonical T1-weighted image in a
standard MNI 152 space.
Functional connectivity analysis: psychophysiological interaction
Psychophysiological interaction (PPI) analyses were used to assess how
activity in a brain region of interest covaried with a source region in
response to the experimental condition (Friston et al., 1997). We exam-
ined functional connectivity from the drug  emotion type interaction
cluster in the left amygdala as a source region to investigate whether this
interaction was related to altered connectivity due to CORT administra-
tion. To test this, we extracted the deconvolved time series from this
cluster (thresholded at p 0.001 uncorrected). The PPI was calculated as
the element-by-element product of this interaction cluster (the first eig-
envariate from the time series of all voxels) and a vector coding for the
effect of task (the contrast “faces fixation”) was entered. This product
was subsequently reconvolved with the hemodynamic response func-
tion, and the resulting interaction term was entered as a regressor in a
first-level model together with the time series of the amygdalar inter-
action cluster and the vector coding for the task effect. The model was
estimated and contrasts generated to test the effects of positive and
negative PPIs. This analysis identified regions that display stronger
functional connectivity with the amygdala during face processing.
Next, the contrast images for the PPI effects were entered in a second-
level analysis for which we used a factorial ANOVA with drug condi-
tion (placebo vs rapid CORT vs slow CORT) as the between-subject
factor, and neuroticism as the covariate. Similar to the conventional
fMRI analyses, regions of interest were corrected for reduced search
regions through anatomical masks as defined by the WFU PickAtlas
Tool (version 2.4). A threshold of p 0.05 whole brain corrected was
applied to all other regions.
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Results
Endocrine and psychological measures
As expected, oral administration of 10 mg of hydrocortisone in-
creased salivary cortisol levels to those observed during severe
stress (Morgan et al., 2000) (Fig. 1) (for absolute values, see sup-
plemental Table S1, available at www.jneurosci.org as supple-
mental material), which was evidenced by a significant time 
group interaction (F(18,114) 28.43; p 0.001). Increased levels
were observed from 30 min after administration onward in both
hydrocortisone administration conditions, and the levels re-
mained elevated for at least 90 min. This resulted in elevated
cortisol levels during fMRI scanning in the rapid hydrocortisone
condition, whereas the levels in the slow condition had already
returned to baseline.
Postexperiment debriefing revealed that participants were not
able to identify the substance received. Furthermore, drug ad-
ministration did not affect mood as assessed three times during
the experiment using the POMSquestion-
naire (supplemental Table S1, available at
www.jneurosci.org as supplemental ma-
terial) (Reddon et al., 1985; Wald and
Mellenbergh, 1990; de Groot, 1992). Al-
though significant reductions in levels
of depression scores (Friedman’s
ANOVA;  2(2) 10.53; p 0.005), anger
scores ( 2(2)  9.09; p  0.011), vigor
scores (2(2) 78.79; p 0.001), and ten-
sion scores (2(2) 21.88; p 0.001) were
observed over the course of the experi-
ment, and levels of fatigue (2(2)  51.18;
p 0.001) increased, none of these factors
was affected by drug administration.
Groups did not differ on any aspect of
mood state at baseline, nor at any other
time point during the experiment (all p
0.05). Changes in mood over time were
also not affected by drug administration
(all p 0.05). The drug manipulation did
not affect the participant’s attentiveness since average reaction
times to the appearance of the fixation cross were not different
across groups (F(2) 1.54, n.s.). Thus, differences in brain activ-
ity found after drug administration cannot readily be explained
by changes in mood or attention.
Brain activation
We first identified brain regions activated by viewing emotional
faces in general. As expected, the face-processing task activated
the amygdala bilaterally. Furthermore, increased activity was ob-
served in a widespread visual processing network, including the
primary visual cortex, extrastriate cortex, and occipitotemporal
regions like the fusiform gyrus, as well as the inferior frontal
gyrus, and the angular and precentral gyrus (supplemental Table
S2, available at www.jneurosci.org as supplemental material).
Second, we looked into the effect of emotion type on brain acti-
vation. The left amygdala was the only brain region that displayed
stronger responses toward fearful than happy faces, whereas the
opposing contrast (happy fearful) did not yield any significant
differences in brain activity (supplemental Table S1, available at
www.jneurosci.org as supplemental material).
To examine how corticosteroids affect emotional processing
over time, we first identified those brain regions whose activity
was modulated by any of the drug conditions. The main effect of
drug revealed that hydrocortisone affected amygdala responsivity
bilaterally (x28, y4, z12; F(2,129) 9.64; pcorrected
0.009; and x  26, y  4, z  12; F(2,129)  7.43; pcorrected 
0.048). Further testing using directed t tests showed that both
hydrocortisone administration conditions significantly re-
duced responses in the amygdala but did not significantly dif-
fer from each other. Thus, hydrocortisone administration in
general reduced amygdala responsivity regardless of timing
(Table 1, Fig. 2A).
Next, we assessed whether this corticosteroid modulation of
brain activity was emotion specific, and tested for an interaction
between drug condition and emotion type. This analysis revealed
a significant interaction in the left amygdala (x26, y4,
z  12; F(2,129)  8.17; pcorrected  0.028) (Fig. 2B). Further
testing showed that this interaction was caused by an emotion-
specific response of the amygdala in the slow hydrocortisone
condition only. Whereas corticosteroids rapidly reduced
amygdala responsivity toward all emotional input, the slow
corticosteroid effects enabled responses to emotionally nega-
tive information, while responses to positive stimuli remained
reduced, resulting in emotion specificity of the amygdala re-
sponse (Table 1, Fig. 2C).
Brain connectivity
To investigate whether these corticosteroid effects on amygdala
responsivity were related to altered amygdala couplingwith brain
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Figure 2. Hydrocortisone affected amygdala responsivity in a time- and emotion-specific manner. A, Main effect of hydrocor-
tisone administration on activity in the amygdala ( y4). Hydrocortisone administration reduced amygdala responsivity to
faces in general, regardless of the timing of administration. B, Drug emotion type interaction in the amygdala ( y4). The
effects of hydrocortisone administration depended on the emotion type. C, Extracted parameter estimates from the anatomically
defined bilateral amygdala revealed that the drug emotion type interaction was driven by a larger emotion effect (fearful
happy) in the slowhydrocortisone condition. Error bars represent SEM. For visualization purposes, both statistical parametricmaps
are thresholded at p 0.005 uncorrected. For statistical tests, see Table 1.
Table 1. Results for main effects of drug and drug emotion interaction
Region
MNI coordinates
t valuex y z
Main effects of drug
Slow CORT placebo
Amygdala, L 22 8 12 3.85**
Amygdala, R 26 4 12 3.82**
Rapid CORT placebo
Amygdala, L 28 4 12 3.91**
Drug emotion interaction
Val(slow CORT) Val(placebo)
Amygdala, L 26 4 12 3.69**
Amygdala, R 24 2 12 3.24*
Val(slow CORT) Val(rapid CORT)
Amygdala, L 26 4 12 3.31*
Peak voxel and corresponding t values of significantly activated clusters. R, Right; L, left; Val, emotional valence
contrast: fearful happy. *p 0.05 small volume corrected for region of interest; **p 0.01 small volume
corrected for region of interest.
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regions involved in its regulation, we performed additional PPI
analyses, seeding the drug by emotion type interaction in the
amygdala. These analyses revealed that the slow effects of corti-
costeroids increased the coupling between the amygdala and the
mPFC compared to the placebo condition (x 10, y 60, z 24;
t(64) 4.38; pcorrected 0.032) (Table 2, Fig. 3A). This effect was
specific for the slow hydrocortisone condition, since it also dif-
fered from the rapid hydrocortisone condition (x  12, y  38,
z 48; t(64) 4.26; pcorrected 0.045) (Table 2, Fig. 3B), with the
latter not being significantly different from placebo. Thus, the slow
effects of corticosteroids induced both the emotion specificity in
amygdala responses and altered its connectivity to the mPFC.
To test whether these two effects were actually associated
rather than independent, we extracted the parameter estimates of
both the emotion effect in amygdala responsivity and the amount
of amygdala–mPFC coupling, and tested whether thesemeasures
were correlated across participants. Even though the PPI analysis
was corrected for amygdala activity fluctuations within each par-
ticipant, this analysis showed that these measures were positively
correlated across participants (r 0.223). Although this correla-
tion just failed to reach significance ( p  0.067), this suggests
that stronger amygdala–mPFC coupling was related to stronger
emotion-specific amygdala responses.
Discussion
In this study, we targeted the time-specific effects of corticoste-
roids on human amygdala functioning by administering hydro-
cortisone at two different time points before an emotional
processing task during fMRI scanning.We found that corticoste-
roids downregulate amygdala responsivity to emotional stimuli
in a time- and emotion-specific manner; whereas corticosteroids
rapidly suppress amygdala responsivity toward all emotional
stimuli, they only suppress responses to positive stimuli later on,
while responses to negative emotional stimuli are normal again.
This emotion-specific recovery of amygdala activity appears re-
lated to altered amygdala connectivity to the medial prefrontal
cortex.
Previous work in animals has indicated that corticosteroids
exert both rapid nongenomic and slow genomic effects that are
functionally distinct (Joe¨ls et al., 2006). At high concentrations,
corticosteroids are shown to rapidly enhance hippocampal plas-
ticity by binding to anMR thought to reside in the plasma mem-
brane, leading to an increase in glutamate release (Karst et al.,
2005). At the same time, a corticosteroid-induced genomic cascade
is initiated by the binding of primarily intracellular GRs that upon
binding translocate to the nucleuswhere they function as transcrip-
tion factors tomodulate the expression of200 genes (Datson et
al., 2001). These slow genomic effects of corticosteroids have
been shown to inhibit hippocampal plasticity (Pavlides et al.,
1995; Wiegert et al., 2005). Here, we dissociated these two effects
experimentally by administering 10 mg of hydrocortisone at ei-
ther 75 or 285 min before the emotional processing task. The
timing of the rapid corticosteroid condition was based on (1)
previous studies in rodents revealing a delay between elevations
in corticosteroid level in plasma versus brain (Droste et al., 2008)
and (2) the observation in humans that salivary cortisol levels
peak at 1 h after intake (Abercrombie et al., 2003). Once in the
brain, these nongenomic corticosteroid effects are rapid in onset
and quickly reversible (Karst et al., 2005). The genomic effects of
corticosteroids, on the other hand, generally do not start earlier
than at least 3 h after exposure to high corticosteroid levels in vivo
(Joe¨ls et al., 2003; Morsink et al., 2006) and these effects last for
hours (Joe¨ls and de Kloet, 1992, 1994; Joe¨ls et al., 2003). Thus,
administration of hydrocortisone at 75 min before scanning
probably caused sufficiently high levels of the hormone in the
brain to evoke rapid nongenomic effects, although this delay
was much too short to allow development of gene-mediated
events. Conversely, when hydrocortisone was applied at 285
min before testing, hormone levels were so low during the
behavioral task that nongenomic actions were not likely to
happen, yet it allowed enough time for the gene-mediated
actions to occur.
Here, we show that corticosteroids rapidly desensitize human
amygdala responses to emotional stimuli. Corticosteroids may
therefore be a crucial factor in terminating a critical feed-forward
loop in the amygdala: acute stress sensitizes the amygdala, and the
amygdala boosts vigilance/anxiety and drives in turn the stress
response. This positive feed-forward loop constitutes a powerful
mechanism leading to progressively augmented amygdala sensi-
tization with repeated stress exposure. The fact that the HPA axis
is dysregulated in stress-related mental disorders such as depres-
sion and PTSD, but also that corticosteroids seem to be effective
in preventing (Schelling et al., 2006) and treating (Aerni et al.,
2004; de Quervain, 2008) PTSD, may speak for their crucial role
in interrupting this positive feed-forward loop.
The anxiolytic effects of corticosteroids observed in previous
studies are in line with the proposed corticosteroid-induced de-
sensitization and thus suppression of vigilance/anxiety. Behav-
ioral studies in humans have shown that corticosteroids reduce
the anxiety-driven selective attention to threat (Putman et al.,
2007; van Peer et al., 2009), attenuate fear responses (Soravia et
al., 2006), and protect mood during exposure to stressful situa-
tions (Het and Wolf, 2007). Here, we provide a mechanistic
account for these observations by showing that the rapid, non-
genomic corticosteroid effects unspecifically desensitize the
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Figure 3. The slow effects of corticosteroids strengthened connectivity between the amyg-
dala and mPFC. A, PPI analyses showed that the slow effects of corticosteroids strengthened
connectivity between the amygdala and a clusterwithin themPFC.B, Analysis of the parameter
estimates of the observedmPFC cluster showed that this altered connectivitywas specific to the
slow hydrocortisone condition, since it significantly differed from that observed in the rapid
hydrocortisone condition (t(43) 3.22; p 0.002). Error bars represent SEM. For visualization
purposes, the statistical parametric map is thresholded at p 0.001 uncorrected. For other
statistical tests, see Table 2.
Table 2. Results of PPI analysis seeding the amygdala
Main effects of drug
MNIcoordinates
t valuex y z
Slow CORT placebo
Medial prefrontal cortex, R 10 60 24 4.38*
Slow CORT rapid CORT
Medial prefrontal cortex, R 12 38 48 4.26*
Peak voxel and corresponding t values of significantly activated clusters inmain effects of drug. R, Right. *p 0.05
small volume corrected for region of interest.
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amygdala. This claim is supported by a previous study showing a
tonic suppressionof the acoustic startle reflex inhumans, thought to
be modulated by the amygdala, which was independent of emo-
tional modulation (Buchanan and Lovallo, 2001).
Two possible, but not mutually exclusive, molecular mecha-
nisms could underlie this corticosteroid-associated reduction in
amygdala activation. First of all, corticosteroids might modulate
amygdala activity in a direct manner by binding to its MRs and
GRs (Sapolsky et al., 1983; Reul and de Kloet, 1985). Corticoste-
roids have been shown to act in such direct manner in the hip-
pocampus, where they rapidly increase neuronal excitability in a
nongenomic fashion by binding to a low-affinity membrane MR
(Karst et al., 2005; Olijslagers et al., 2008) and slowly impair
hippocampal function by binding intracellular MRs and GRs.
Corticosteroids could affect amygdala function in a similar man-
ner, but supporting evidence for this idea is so far scarce (Karst et
al., 2002; Duvarci and Pare, 2007; Pu et al., 2009). Alternatively,
the corticosteroid effects might be mediated by a reduction in
brain levels of corticotrophin-releasing hormone (CRH). CRH is
a coordinator of the central stress response, and is known to induce
anxious behavior by activating the human amygdala both directly
(Liang and Lee, 1988) and indirectly by increasing locus ceruleus
norepinephrine signaling (Valentino et al., 1983; Valentino and
Foote, 1988). Since CRH levels are known to be inhibited by the
negative feedback actions of corticosteroids on the hypothalamus
(Keller-Wood and Dallman, 1984; Herman et al., 1996; Tasker,
2006; Aguilera et al., 2007), corticosteroid-induced reductions in
circulating CRH levels could also explain our findings. Thus,
corticosteroids rapidly inhibit amygdala activity either by direct
modulation or by reducing circulating CRH levels, and thereby
protect the amygdala during stress from potential overshoot by
the sensitizing actions of NE and CRH.
One might also argue that an altered mood state during scan-
ning could underlie the observed changes in amygdala response.
We cannot exclude this possibility since we did not assess mood
just before or during scanning.However,mood statewas assessed
three times during the study and appeared not to be affected by
either a history of elevation in cortisol levels (mood measure 2
and 3 for the slow CORT group) (Fig. 1) or an acutely elevated
level (mood measure 3 rapid CORT group) (Fig. 1). Therefore,
we consider it unlikely that mood during scanning was different
between groups.
The slow effects of corticosteroids, on the other hand, normal-
ized responses to negative input, whereas responses to positive
input remained suppressed. Moreover, the induction of this
emotion specificity in the amygdala seemed to be related to in-
creased coupling with the mPFC. The mPFC is known to play a
significant role in emotion regulation (Ochsner andGross, 2005),
and suppresses the amygdala during the regulation of emotional
responses to negative stimuli (Beauregard et al., 2001; Kompus et
al., 2009). Further, themPFC is known to play a critical role in the
control over the HPA axis. The mPFC expresses high levels of
glucocorticoid receptors (Diorio et al., 1993; Sa´nchez et al., 2000)
and is a prominent target for the negative feedback control over
the HPA axis (Sullivan and Gratton, 2002; Radley et al., 2009).
Activation of themPFC has been shown to reduce stress-induced
salivary cortisol increases, but also amygdala activity and dispo-
sitional mood state (Kern et al., 2008). Here, we show that the
connectivity between the amygdala andmPFC is strengthened by
the slow, putatively genomic, actions of corticosteroids. More-
over, this strengthening seemed to enhance the preferential pro-
cessing of negative over positive emotional stimuli. This suggests
that the slow actions of corticosteroids ensure recovery of the
rapid effects of corticosteroids on amygdala responses to negative
input specifically by changing regulatory actions of the mPFC.
This could entail a highly adaptive mechanism for survival, since
it is most important to be capable to respond adequately to dan-
gerous stimuli first.
Here we reveal an adaptive mechanism of time-dependent
amygdala modulation by corticosteroids; rapid nongenomic ef-
fects of corticosteroids suppress overall amygdala activity in an
unspecific manner, whereas slow genomic actions of corticoste-
roids upregulate (i.e., normalize) responses to negative input spe-
cifically by altered prefrontal control. In response to stress,
corticosteroids thereby rapidly guard amygdala activation from
potential overshoot by the sensitizing actions of NE and CRH,
and normalize amygdala response later on, prioritizing negative
emotional processing. Thus, corticosteroids control amygdala re-
sponsivity and vigilance/anxiety, and appear therefore as a crucial
factor when the stress response has to be terminated adequately
in the aftermath of traumatic experiences.
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